What is it about?
A look at results we've experienced for patients that continue to lack symptom control for Gastroparesis after standard medications and gastric stimulation. This paper examines relationships between Gastroparesis and the Autoimmune system and the outcomes of Immunoglobulin Infusions (IVIG) for treatment to improve symptoms alone and/or with other previous methods failed.
Featured Image
Why is it important?
In a time that there is so much focus on decreasing healthcare costs and becoming more preventative minded, being able to find better and more effective treatment options for this rare disease and many others is imperative. This is a start in identifying better treatment options as well as looking at causes of the disease that may appear to be dissociated. We identify that those with positive Autoimmune antibodies and receive IVIG treatment have better symptom control and in the long run that will decrease Healthcare costs for this population and improve quality of life.
Perspectives
I am honored to be a co-author with such a fantastic group and on a Health issue that has little understanding in the Healthcare world and general population but big impacts to the costs of Healthcare and the lives of those who suffer from it. I hope this article can bring some understanding, open dialogue, and bring about more research on this disease and all rare diseases.
Tiff Howell
Jewish Hospital Louisville,KY.
Read the Original
This page is a summary of: Intravenous immunoglobulin in drug and device refractory patients with the symptoms of gastroparesis-an open-label study, Neurogastroenterology & Motility, December 2017, Wiley,
DOI: 10.1111/nmo.13256.
You can read the full text:
Contributors
The following have contributed to this page
